Anthony Petrone
Stock Analyst at Mizuho
(4.16)
# 479
Out of 5,090 analysts
201
Total ratings
54.48%
Success rate
12.22%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $85 → $100 | $81.40 | +22.85% | 16 | Dec 5, 2025 | |
| AXGN Axogen | Initiates: Outperform | $40 | $33.32 | +20.05% | 1 | Dec 1, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $65 → $70 | $63.36 | +10.48% | 9 | Nov 13, 2025 | |
| ALC Alcon | Maintains: Outperform | $110 → $100 | $80.73 | +23.87% | 11 | Nov 11, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $70 → $85 | $70.79 | +20.07% | 8 | Nov 6, 2025 | |
| RMD ResMed | Maintains: Outperform | $310 → $300 | $256.55 | +16.94% | 18 | Oct 31, 2025 | |
| EW Edwards Lifesciences | Maintains: Outperform | $90 → $100 | $86.19 | +16.02% | 10 | Oct 31, 2025 | |
| HOLX Hologic | Downgrades: Neutral | $70 → $78 | $74.97 | +4.04% | 10 | Oct 23, 2025 | |
| GH Guardant Health | Maintains: Outperform | $65 → $70 | $102.02 | -31.39% | 3 | Sep 25, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $90 → $70 | $83.94 | -16.61% | 15 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $70 | $63.30 | +10.58% | 6 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $120.50 | +12.03% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $125.08 | +7.93% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $25.38 | -29.08% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $101.36 | -1.34% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $11.69 | +2.65% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $100 | $65.49 | +52.70% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $108.51 | +61.28% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.62 | +504.23% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $20.92 | -4.40% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $101.06 | -40.63% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $81.77 | -29.07% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $110 | $97.52 | +12.80% | 8 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $19.85 | -29.47% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $85.46 | +22.86% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $136.81 | +82.74% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $6.93 | +102.02% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $575.34 | -32.21% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $84.53 | -20.74% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $94.28 | +85.62% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $11.58 | +115.89% | 3 | May 13, 2020 |
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $81.40
Upside: +22.85%
Axogen
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $33.32
Upside: +20.05%
LivaNova
Nov 13, 2025
Maintains: Outperform
Price Target: $65 → $70
Current: $63.36
Upside: +10.48%
Alcon
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $80.73
Upside: +23.87%
Establishment Labs Holdings
Nov 6, 2025
Maintains: Outperform
Price Target: $70 → $85
Current: $70.79
Upside: +20.07%
ResMed
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $256.55
Upside: +16.94%
Edwards Lifesciences
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $86.19
Upside: +16.02%
Hologic
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $74.97
Upside: +4.04%
Guardant Health
Sep 25, 2025
Maintains: Outperform
Price Target: $65 → $70
Current: $102.02
Upside: -31.39%
Haemonetics
Aug 8, 2025
Maintains: Outperform
Price Target: $90 → $70
Current: $83.94
Upside: -16.61%
Aug 7, 2025
Maintains: Outperform
Price Target: $120 → $70
Current: $63.30
Upside: +10.58%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $120.50
Upside: +12.03%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $125.08
Upside: +7.93%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $25.38
Upside: -29.08%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $101.36
Upside: -1.34%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $11.69
Upside: +2.65%
Jul 16, 2025
Maintains: Outperform
Price Target: $95 → $100
Current: $65.49
Upside: +52.70%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $108.51
Upside: +61.28%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $6.62
Upside: +504.23%
Apr 10, 2025
Initiates: Neutral
Price Target: $20
Current: $20.92
Upside: -4.40%
Apr 10, 2025
Initiates: Outperform
Price Target: $60
Current: $101.06
Upside: -40.63%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $81.77
Upside: -29.07%
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $97.52
Upside: +12.80%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $19.85
Upside: -29.47%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $85.46
Upside: +22.86%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $136.81
Upside: +82.74%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $6.93
Upside: +102.02%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $575.34
Upside: -32.21%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $84.53
Upside: -20.74%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $94.28
Upside: +85.62%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $11.58
Upside: +115.89%